Carmat announces the issuance of a second tranche of equity warrants within the framework of its contingent equity line with Kepler Cheuvreux

CARMAT (FR0010907956, ALCAR), the designer and developer of the world’s most advanced total artificial heart, aiming to fulfill an unmet medical need by providing a therapeutic alternative to people suffering from end-stage  biventricular  heart  failure,  today  announces the  issuance  of  a  secondtranche of650,000 equity warrants within the framework of thecontingentequityline withKepler Cheuvreux.

On September27,2018, CARMAT put in place acontingentequity line contractwithKepler Cheuvreuxfor a maximum amount of €25 million for a duration of 3 years.

The firsttranche of400,000 equity warrants,issued inSeptember2018, has, to date, enabled the Company to benefitfrom €9.1 million in financing within the framework of this contract.